Literature DB >> 34303699

Myeloid Cells Are Enriched in Tonsillar Crypts, Providing Insight into the Viral Tropism of Human Papillomavirus.

Austin K Mattox1, Jessica Roelands2, Talia M Saal3, Yang Cheng3, Darawan Rinchai4, Wouter Hendrickx4, Geoffrey D Young5, Thomas J Diefenbach6, Alan E Berger7, William H Westra8, Justin A Bishop9, William C Faquin10, Francesco M Marincola11, Mikael J Pittet12, Davide Bedognetti4, Sara I Pai13.   

Abstract

Viruses are the second leading cause of cancer worldwide, and human papillomavirus (HPV)-associated head and neck cancers are increasing in incidence in the United States. HPV preferentially infects the crypts of the tonsils rather than the surface epithelium. The present study sought to characterize the unique microenvironment within the crypts to better understand the viral tropism of HPV to a lymphoid-rich organ. Laser-capture microdissection of distinct anatomic areas (crypts, surface epithelium, and germinal centers) of the tonsil, coupled with transcriptional analysis and multiparameter immunofluorescence staining demonstrated that the tonsillar crypts are enriched with myeloid populations that co-express multiple canonical and noncanonical immune checkpoints, including PD-L1, CTLA-4, HAVCR2 (TIM-3), ADORA2A, IDO1, BTLA, LGALS3, CDH1, CEACAM1, PVR, and C10orf54 (VISTA). The resident monocytes may foster a permissive microenvironment that facilitates HPV infection and persistence. Furthermore, the myeloid populations within HPV-associated tonsil cancers co-express the same immune checkpoints, providing insight into potential novel immunotherapeutic targets for HPV-associated head and neck cancers.
Copyright © 2021 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34303699      PMCID: PMC8491092          DOI: 10.1016/j.ajpath.2021.06.012

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   5.770


  23 in total

1.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository.

Authors:  Ron Edgar; Michael Domrachev; Alex E Lash
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

Review 2.  Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region.

Authors:  Hisham Mehanna; Tom Beech; Tom Nicholson; Iman El-Hariry; Christopher McConkey; Vinidh Paleri; Sally Roberts
Journal:  Head Neck       Date:  2012-01-20       Impact factor: 3.147

3.  Global burden of cancers attributable to infections in 2012: a synthetic analysis.

Authors:  Martyn Plummer; Catherine de Martel; Jerome Vignat; Jacques Ferlay; Freddie Bray; Silvia Franceschi
Journal:  Lancet Glob Health       Date:  2016-07-25       Impact factor: 26.763

Review 4.  Natural killer cells in antiviral defense: function and regulation by innate cytokines.

Authors:  C A Biron; K B Nguyen; G C Pien; L P Cousens; T P Salazar-Mather
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

5.  GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death.

Authors:  Matthew J Streetly; Lenushka Maharaj; Simon Joel; Steve A Schey; John G Gribben; Finbarr E Cotter
Journal:  Blood       Date:  2010-02-26       Impact factor: 22.113

Review 6.  Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment.

Authors:  Sara I Pai; William H Westra
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

Review 7.  Galectins and Carcinogenesis: Their Role in Head and Neck Carcinomas and Thyroid Carcinomas.

Authors:  Nadège Kindt; Fabrice Journe; Ghanem E Ghanem; Sven Saussez
Journal:  Int J Mol Sci       Date:  2017-12-18       Impact factor: 5.923

Review 8.  The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment.

Authors:  Mohammad Farhad; Annah S Rolig; William L Redmond
Journal:  Oncoimmunology       Date:  2018-02-20       Impact factor: 8.110

9.  An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.

Authors:  Tariq Sethi; Alison C MacKinnon; Lynda Vuong; Eleni Kouverianou; Claire M Rooney; Brian J McHugh; Sarah E M Howie; Christopher D Gregory; Stuart J Forbes; Neil C Henderson; Fredrik R Zetterberg; Ulf J Nilsson; Hakon Leffler; Paul Ford; Anders Pedersen; Lise Gravelle; Susan Tantawi; Hans Schambye
Journal:  Cancer Res       Date:  2019-01-23       Impact factor: 12.701

10.  VISTA Regulates the Development of Protective Antitumor Immunity.

Authors:  Isabelle Le Mercier; Wenna Chen; Janet L Lines; Maria Day; Jiannan Li; Petra Sergent; Randolph J Noelle; Li Wang
Journal:  Cancer Res       Date:  2014-04-01       Impact factor: 12.701

View more
  3 in total

1.  Development of a Spontaneous HPV16 E6/E7-Expressing Head and Neck Squamous Cell Carcinoma in HLA-A2 Transgenic Mice.

Authors:  Shiwen Peng; Deyin Xing; Louise Ferrall; Ya-Chea Tsai; Richard B S Roden; Chien-Fu Hung; T-C Wu
Journal:  mBio       Date:  2022-01-04       Impact factor: 7.867

Review 2.  Heparan Sulfate and Sialic Acid in Viral Attachment: Two Sides of the Same Coin?

Authors:  Ivan Emmanuel Ramos-Martínez; Edgar Ramos-Martínez; René Álvaro Segura-Velázquez; Manuel Saavedra-Montañez; Jacquelynne Brenda Cervantes-Torres; Marco Cerbón; Dulce Papy-Garcia; Edgar Zenteno; José Ivan Sánchez-Betancourt
Journal:  Int J Mol Sci       Date:  2022-08-30       Impact factor: 6.208

Review 3.  The Drivers, Mechanisms, and Consequences of Genome Instability in HPV-Driven Cancers.

Authors:  Vanessa L Porter; Marco A Marra
Journal:  Cancers (Basel)       Date:  2022-09-23       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.